IOncology

At SABCS 2024, Professor Ian Kunkler presented the 10-year results of the SUPREMO trial, a phase III study evaluating the role of postmastectomy radiotherapy (PMRT) in intermediate-risk breast cancer. The trial aimed to determine whether PMRT improves overall survival in patients with 1-3 positive lymph nodes or high-risk node-negative disease.

At SABCS 2024, Dr. Icro Meattini presented a preplanned interim analysis of the EUROPA trial, a randomized phase III study comparing exclusive endocrine therapy (ET) vs. radiation therapy (RT) in women aged 70+ with luminal-like early breast cancer. The study aimed to evaluate quality of life (HRQOL) and ipsilateral breast tumor recurrence (IBTR) to guide treatment decisions in this patient population.

Throwback to SABCS 2024, where Dr. Mafalda Oliveira presented findings from the SOLTI VALENTINE phase II trial, evaluating HER3-DXd alone or in combination with letrozole as a neoadjuvant treatment for high-risk HR+/HER2-negative early breast cancer (EBC). The study explored whether HER3-DXd could serve as an effective and tolerable alternative to standard multi-agent chemotherapy.

The Influence of Gut Microbiota on CRC Risk The gut microbiome plays a critical role in colorectal cancer (CRC) development, prognosis, and treatment response. Dr. Andrew T. Chan's presentation at…

The landscape of systemic therapies for advanced esophagogastric cancer (EGC) has evolved significantly with the integration of immunotherapeutic and targeted treatment strategies. This article summarizes the key findings from Dr.…

Malignant melanocytes can appear in various tissues throughout the body, most commonly in the skin and mucous membranes, and are highly aggressive. With continuous advancements in targeted therapy, immunotherapy, and biological therapy, even advanced melanoma can, in many cases, be managed as a chronic disease. Looking back at 2024, what were the key research developments and treatment strategies in systemic therapy for melanoma? Oncology Frontier invited Dr. Jun Guo, Vice President of the Chinese Society of Clinical Oncology (CSCO) and professor at Peking University Cancer Hospital, to provide an expert review and summary. From Professor Guo’s annual analysis, it is evident that numerous novel treatment strategies have already begun or are poised to impact clinical practice, including some pioneering approaches originating from China.

The 2024 European Society for Medical Oncology Asia Congress (ESMO Asia 2024) was recently held in Singapore, where the DESTINY-Gastric06 (DG06) trial presented its latest findings, sparking widespread discussion. We…

Microsatellite stable (MSS) and mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC) has shown minimal response to immune checkpoint inhibitors as monotherapy, making combination immunotherapy a key strategy to address this clinical challenge. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), a multicenter phase II study led by Dr. Rongbo Lin from Fujian Cancer Hospital was selected for the poster abstract session (Abstract #198). This study evaluates the preliminary efficacy and safety of FOLFOXIRI combined with bevacizumab and cadonilimab in pMMR/MSS mCRC patients.  During the conference, a reporter from Oncology Frontier conducted an in-depth interview with Dr. Rongbo Lin to discuss the study findings.

From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, showcasing significant advancements in gastrointestinal cancer treatment. The Peking University Cancer Hospital presented a series of cutting-edge findings, contributing to global progress in digestive tract oncology. On the first day of the conference, Dr. Zhi Peng from Peking University Cancer Hospital delivered an oral presentation on the latest findings from a Phase III clinical study evaluating the domestically developed PD-L1/TGF-βRII bispecific fusion protein SHR-1701 in first-line treatment for HER2-negative gastric and gastroesophageal junction adenocarcinoma (G/GEJA). Building upon the efficacy improvements previously reported at the European Society for Medical Oncology (ESMO) Congress, the latest data presented at ASCO GI suggests that SHR-1701 combined with chemotherapy may mitigate chemotherapy-induced bone marrow suppression, offering a more effective and safer treatment option for G/GEJA.

Dr. Charles Geyer, Jr.. presented findings from the NSABP B-59/GBG-96-GeparDouze phase III trial, evaluating the addition of atezolizumab to neoadjuvant chemotherapy, followed by adjuvant atezolizumab, in stage II-III triple-negative breast cancer (TNBC).